DE602006004463D1 - Kristallform von asenapinmaleat - Google Patents

Kristallform von asenapinmaleat

Info

Publication number
DE602006004463D1
DE602006004463D1 DE602006004463T DE602006004463T DE602006004463D1 DE 602006004463 D1 DE602006004463 D1 DE 602006004463D1 DE 602006004463 T DE602006004463 T DE 602006004463T DE 602006004463 T DE602006004463 T DE 602006004463T DE 602006004463 D1 DE602006004463 D1 DE 602006004463D1
Authority
DE
Germany
Prior art keywords
asenapinmaleate
crystal form
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006004463T
Other languages
English (en)
Inventor
Gerhardus Johannes Heeres
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Organon NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36617328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602006004463(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Organon NV filed Critical Organon NV
Publication of DE602006004463D1 publication Critical patent/DE602006004463D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
DE602006004463T 2005-04-07 2006-04-06 Kristallform von asenapinmaleat Active DE602006004463D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05102742 2005-04-07
EP05102969 2005-04-14
PCT/EP2006/061408 WO2006106135A1 (en) 2005-04-07 2006-04-06 Crystal form of asenapine maleate

Publications (1)

Publication Number Publication Date
DE602006004463D1 true DE602006004463D1 (de) 2009-02-05

Family

ID=36617328

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602006000080T Active DE602006000080T2 (de) 2005-04-07 2006-04-06 Kristallform von Asenapinmaleat
DE602006004463T Active DE602006004463D1 (de) 2005-04-07 2006-04-06 Kristallform von asenapinmaleat

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE602006000080T Active DE602006000080T2 (de) 2005-04-07 2006-04-06 Kristallform von Asenapinmaleat

Country Status (31)

Country Link
EP (2) EP1710245B1 (de)
JP (1) JP5058151B2 (de)
KR (1) KR101422843B1 (de)
AR (1) AR056306A1 (de)
AT (2) ATE370954T1 (de)
AU (1) AU2006231617B2 (de)
BR (1) BRPI0609741A8 (de)
CA (1) CA2603509C (de)
CY (2) CY1106902T1 (de)
DE (2) DE602006000080T2 (de)
DK (2) DK1710245T3 (de)
DO (1) DOP2006000082A (de)
ES (2) ES2318742T3 (de)
GT (1) GT200600135A (de)
HN (1) HN2006014095A (de)
HR (1) HRP20070429T3 (de)
IL (1) IL186355A (de)
MX (1) MX2007012445A (de)
MY (1) MY137969A (de)
NO (1) NO340520B1 (de)
NZ (1) NZ562124A (de)
PE (1) PE20061311A1 (de)
PL (2) PL1917267T3 (de)
PT (2) PT1917267E (de)
RS (1) RS50532B (de)
RU (1) RU2405786C2 (de)
SI (2) SI1710245T1 (de)
SV (1) SV2006002473A (de)
TW (1) TWI364423B (de)
UY (1) UY29459A1 (de)
WO (1) WO2006106135A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002891A1 (es) * 2006-10-06 2008-04-18 Organon Nv Trans-5-cloro-2-metil-2,3,3a,12b-tetrahidro-1h-dibenz-[2,3:6,7]oxepino[4,5-c]pirrol 50% amorfo en base al peso total del compuesto; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de un trastorno seleccionado entre e
KR101435296B1 (ko) * 2009-06-24 2014-08-27 머크 샤프 앤 도메 비.브이. 아세나핀을 함유하는 주사가능한 제제 및 그를 사용한 치료 방법
US8779161B2 (en) 2010-06-18 2014-07-15 Dr. Reddy's Laboratories Limited Asenapine maleate
WO2012066565A2 (en) * 2010-11-16 2012-05-24 Cadila Healthcare Limited Asenapine maleate amorphous and crystalline form and process for preparation thereof
EP2468750A1 (de) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphe Formen von Asenapinmaleat und Verfahren zur ihrer Herstellung
WO2012123325A1 (en) 2011-03-11 2012-09-20 Medichem S.A. NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
ITMI20110734A1 (it) * 2011-05-02 2012-11-03 Olon Spa Sali cristallini di asenapina
EP2524919A1 (de) 2011-05-17 2012-11-21 Sandoz AG Neue kristalline Salze von Asenapin mit organischen Di-Säuren und Tri-Säuren
EP2524921A1 (de) 2011-05-17 2012-11-21 Sandoz AG Neue kristalline Salze von Asenapin
EP2524920A1 (de) 2011-05-17 2012-11-21 Sandoz AG Neue kristalline Formen von Asenapin-Hydrochloridsalz
EP2709615A1 (de) 2011-05-18 2014-03-26 Laboratorios Lesvi, S.L. Monokline kristalline form von asenapin-maleat mit bestimmter teilchengroessenverteilung
JP6014656B2 (ja) * 2011-05-18 2016-10-25 ラビラトリオス レスビ エス エレ 化合物の多形体
EP2572703A1 (de) 2011-09-21 2013-03-27 Hexal AG Komprimierte orale Dosierform für Asenapinmaleat
WO2013041604A1 (en) 2011-09-21 2013-03-28 Sandoz Ag Crystal form of asenapine maleate
JP6005742B2 (ja) * 2012-07-26 2016-10-12 久光製薬株式会社 貼付剤
ITMI20121810A1 (it) 2012-10-24 2014-04-25 Chemo Iberica Sa Poliformi di maleato di asenapina e processo per la loro preparazione
WO2014090386A1 (en) 2012-12-11 2014-06-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Orally disintegrating tablet containing asenapine
WO2014127786A1 (en) 2013-02-22 2014-08-28 Zentiva, K.S. Orally disintegrating pharmaceutical composition comprising asenapine
WO2017037718A1 (en) 2015-09-02 2017-03-09 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders
US20180193283A1 (en) 2016-12-20 2018-07-12 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CA3047354A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
BR112020026099A2 (pt) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
PL180465B1 (pl) * 1994-03-02 2001-02-28 Akzo Nobel Nv Kompozycja farmaceutyczna zawierajaca trans-5-chloro-2-metylo-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oksepino[4,5-c]pirol PL PL PL
WO1999032108A1 (en) * 1997-12-19 1999-07-01 Akzo Nobel N.V. Org-5222 in the treatment of depression
TWI327915B (en) * 2003-06-12 2010-08-01 Organon Nv Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight

Also Published As

Publication number Publication date
RS50532B (sr) 2010-05-07
SI1710245T1 (sl) 2007-12-31
DE602006000080T2 (de) 2008-05-15
PT1710245E (pt) 2007-10-03
HN2006014095A (es) 2010-08-19
EP1710245B1 (de) 2007-08-22
ATE418556T1 (de) 2009-01-15
EP1710245A1 (de) 2006-10-11
BRPI0609741A8 (pt) 2018-03-13
MX2007012445A (es) 2007-11-07
NO20075142L (no) 2007-11-05
TW200722428A (en) 2007-06-16
CY1106902T1 (el) 2012-09-26
CA2603509C (en) 2013-12-03
HRP20070429T3 (en) 2007-11-30
CY1108742T1 (el) 2014-04-09
AU2006231617A1 (en) 2006-10-12
KR101422843B1 (ko) 2014-07-24
AU2006231617B2 (en) 2010-06-03
GT200600135A (es) 2006-11-07
PT1917267E (pt) 2009-02-04
PL1917267T3 (pl) 2009-06-30
IL186355A0 (en) 2008-01-20
PL1710245T3 (pl) 2008-01-31
DOP2006000082A (es) 2006-11-30
JP2008534656A (ja) 2008-08-28
KR20080005253A (ko) 2008-01-10
BRPI0609741A2 (pt) 2010-04-27
MY137969A (en) 2009-04-30
PE20061311A1 (es) 2007-02-09
JP5058151B2 (ja) 2012-10-24
TWI364423B (en) 2012-05-21
EP1917267A1 (de) 2008-05-07
NO340520B1 (no) 2017-05-02
WO2006106135A1 (en) 2006-10-12
SV2006002473A (es) 2009-11-24
ES2293626T3 (es) 2008-03-16
EP1917267B1 (de) 2008-12-24
CA2603509A1 (en) 2006-10-12
ATE370954T1 (de) 2007-09-15
NZ562124A (en) 2010-07-30
ES2318742T3 (es) 2009-05-01
UY29459A1 (es) 2006-11-30
RU2405786C2 (ru) 2010-12-10
RU2007141198A (ru) 2009-05-20
AR056306A1 (es) 2007-10-03
DK1917267T3 (da) 2009-04-14
SI1917267T1 (sl) 2009-04-30
DK1710245T3 (da) 2007-12-03
IL186355A (en) 2016-05-31
DE602006000080D1 (de) 2007-10-04

Similar Documents

Publication Publication Date Title
DE602006004463D1 (de) Kristallform von asenapinmaleat
DE602005012267D1 (de) N von geräten
ATE528296T1 (de) Polymorphe form von 4-ä3-(4- cyclopropancarbonylpiperazin-1-carbonyl)-4- fluorbenzylü-2h-phthalazin-1-on
DK1720866T3 (da) Fremgangsmåde
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
DK1917227T3 (da) Krystalformer af astaxanthin
CY2013046I2 (el) Καινοτομος χρηση των αντισωματων αντι il-1bhta
DE602007002135D1 (de) Kristalloszillator
ATE460162T1 (de) Neue kristallformen von irinotecan-hydrochlorid
DE602007012260D1 (de) Nitratester von piperidinen
DE502006007287D1 (de) N von werkstücken
DE602005012754D1 (de) Kristalloszillator
DE602005006734D1 (de) Uhrwerk
FI20055133A0 (fi) Iskulaite
FR2877833B1 (fr) Correcteur de lordoses
ATE410417T1 (de) Kristallmodifikationen von triazinylaminostilbenen
ITMI20052170A1 (it) Forma cristallina di protriptilina cloridrato
UA12593S (uk) Стела-цінник світива
FR2865930B3 (fr) Civiere de commodite
FI20041228A (fi) Hiomakiven kunto
UA11801S (uk) Черепиця фронтонна
UA11802S (uk) Черепиця фронтонна
FI20050571A0 (fi) Käyttömenetelmä
UA11794S (uk) Комплект етикеток
UA12425S (uk) Комплект етикеток

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1917267

Country of ref document: EP

Representative=s name: WUESTHOFF & WUESTHOFF PATENT- UND RECHTSANWAEL, DE